Register for the webinar here:

The Dos & Don’ts of Fundraising

Insights from Viva BioInnovator

9:00AM – 10:00AM China Standard Time

5:00PM – 6:00PM Pacific Time (7 Dec)

8:00PM – 9:00PM Eastern Time (7 Dec)

Capital is the crux of a start-up’s success, but fundraising can often be the trickiest part to navigate as an early-stage innovator. Looking for help? We’ve got experts in to share their experience via some simple “dos and don’ts” with the aim to help you on your way to fundraising.

Join us as we seek advice from Johnson & Johnson Innovation – JLABS’ Investor Hub member, Viva BioInnovator, as well residents from the JLABS @ Shanghai portfolio from all walks of fundraising life to share their top tips.

Speaking on the panel will be:

Dr. Han Dai - CBO, Viva Biotech and Head of Investment, Viva BioInnovator - Before this role, Han was Senior Director of New Ventures at Johnson & Johnson Innovation, responsible for developing and implementing Innovation strategies, creating a deep and credible network with innovators and entrepreneurs. Prior to that, he held multiple roles with increasing responsibilities as Scientific Leader and GSK Fellow of Protein Degradation DPU/Future Pipeline Discovery team at GlaxoSmithKline US headquarter. Han has ~20 years’ experience in the pharma/biotech industry with track records of successful leadership in small molecule & biologics drug discovery & development and high-profile publications

Chloe Kamps - Alliance Manager, Viva BioInnovator - Chloe previously worked in the Florida Senate, where she acted as a legislative aide and office manager focusing on policy review for regulated industries. She went on to work in the nonprofit sector as a community organizer and lobbyist advocating for growth and development of the nonprofit sector. Chloe then moved to the private sector, where she worked for a biotech fund in investor relations before starting with VBI in 2018 where she focuses on the identification of new portfolio companies and building out VBI's innovation ecosystem.

Lily Zou - Co-founder and CEO, Degron Therapeutics - Prior to joining Degron, Lily was President and CEO of Fosun Pharma USA and Vice President of Fosun Pharma Group, where she built and grew Fosun Pharma’s US business, which has R&D, regulatory, and commercialization capabilities in the US market. Fosun Pharma USA also invests and incubates innovative technologies via its incubator FUSION Bioventures. Lily was Chairman of the Board and Chief Business Officer of Archimmune Therapeutics, a portfolio company of FUSION Bioventures, and board member of Nature’s Sunshine Products (NASDAQ: NATR), NovelStar and Glycotest.

Sharon Chan - Head of JLABS @ Shanghai, Johnson & Johnson Innovation - Sharon is responsible for setting the strategic direction and overseeing all operational activities for JLABS @ Shanghai, the first Johnson & Johnson Innovation – JLABS in Asia Pacific and the largest in its global network. Her responsibilities include managing the portfolio of JLABS in the region and collaborating with its internal and external business partners across multiple sectors to implement educational programming and drive high-quality company sourcing from innovation hotspots across Asia Pacific. In 2020, Sharon was recognized by Forbes China as one of the 50 Top Women in Tech.

Julien Dedman - Strategic Marketing, Communication and Public Affairs Leader, Johnson & Johnson Innovation, Asia Pacific - In this role, Julien is responsible for developing, leading, and executing a comprehensive, integrated Marketing, Communication and Public Affairs strategy for Johnson & Johnson Innovation - JLABS in the region. He is responsible for driving awareness of organization’s value proposition through initiatives such as digital marketing, programming, and stakeholder relations with the goal of building a world-class portfolio of resident companies that adds value to Johnson & Johnson.